Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial

作者：Klaus G Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann‐Menke, G. H. Heine, Hui Cao, J Schorr, Philippe Ferber, Jing Wang, Enrico Cristante, Björn Müller‐Edenborn, Anja Vogt, Volker Schettler, Elisabeth Steinhagen-Thiessen · 发表于：European Heart Journal · 年份：2026 · DOI：10.1093/eurheartj/ehag073 · 被引用次数：6 · 研究领域：Coagulation, Bradykinin, Polyphosphates, and Angioedema、Lipoproteins and Cardiovascular Health、Lipid metabolism and disorders

BACKGROUND AND AIMS: Lipoprotein apheresis (LA) is the only approved treatment for patients with elevated lipoprotein(a) [Lp(a)]. The Lp(a)FRONTIERS APHERESIS trial investigated whether pelacarsen reduces the need for LA in patients from Germany with elevated Lp(a) and established cardiovascular disease (CVD). METHODS: Adult patients with Lp(a) levels >60 mg/dl who had undergone ≥35 LA sessions in the prior year were randomized to receive pelacarsen 80 mg or placebo every 4 weeks for 52 weeks. Weekly LA sessions were performed if the Lp(a) measurement from the prior visit was >60 mg/dL. The primary endpoint was the rate of performed LA sessions normalized to the weekly LA schedule (the number of actual LA sessions divided by the number of planned LA sessions during the 52-week period). Secondary endpoints were time to LA avoidance (for ≥24 consecutive weeks) and total LA avoidance from week 12 to week 52. RESULTS: Fifty-one patients were randomized (mean age 61.7 years, mean Lp(a) at baseline 85.4 mg/dL, and mean 44.0 LA sessions in the past 12 months), with 25 of 26 (96.2%) in the pelacarsen arm and 23 of 25 (92.0%) in the placebo arm completing the study. Baseline characteristics were generally balanced between treatment arms. Pelacarsen reduced the mean rates of LA (0.16 vs 0.93 in placebo, odds ratio 0.006, 95% confidence interval [CI] 0.003, 0.013; P < .0001) and substantially increased the hazard of achieving LA avoidance (hazard ratio: 88.3; P = .0014; median time to a...